0000880771-17-000069.txt : 20170428
0000880771-17-000069.hdr.sgml : 20170428
20170428174955
ACCESSION NUMBER: 0000880771-17-000069
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170426
FILED AS OF DATE: 20170428
DATE AS OF CHANGE: 20170428
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SCICLONE PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0000880771
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 943116852
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 950 TOWER LANE
STREET 2: SUITE 900
CITY: FOSTER CITY
STATE: CA
ZIP: 94404-2125
BUSINESS PHONE: 650-358-3456
MAIL ADDRESS:
STREET 1: 950 TOWER LANE
STREET 2: SUITE 900
CITY: FOSTER CITY
STATE: CA
ZIP: 94404-2125
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Blobel Friedhelm
CENTRAL INDEX KEY: 0001363213
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19825
FILM NUMBER: 17797572
MAIL ADDRESS:
STREET 1: 950 TOWER LANE, SUITE 900
CITY: FOSTER CITY
STATE: CA
ZIP: 94404
4
1
certent-form4.xml
PRIMARY DOCUMENT
X0306
4
2017-04-26
0000880771
SCICLONE PHARMACEUTICALS INC
SCLN
0001363213
Blobel Friedhelm
950 TOWER LANE, SUITE 900
FOSTER CITY
CA
94404
1
1
0
0
President & CEO
Common Stock
2017-04-26
4
M
0
1400
3.55
A
93926
D
Common Stock
2017-04-26
4
S
0
1400
10.00
D
92526
D
Common Stock
2017-04-27
4
M
0
2800
3.55
A
95326
D
Common Stock
2017-04-27
4
S
0
2800
10.0081
D
92526
D
Common Stock
2017-04-28
4
M
0
200
3.55
A
92726
D
Common Stock
2017-04-28
4
S
0
200
10
D
92526
D
Non-Qualified Stock Option (right to buy)
3.55
2017-04-26
4
M
0
1400
0
D
2020-03-05
Common Stock
1400
209000
D
Non-Qualified Stock Option (right to buy)
3.55
2017-04-27
4
M
0
2800
0
D
2020-03-05
Common Stock
2800
206200
D
Non-Qualified Stock Option (right to buy)
3.55
2017-04-28
4
M
0
200
0
D
2020-03-05
Common Stock
200
206000
D
The reported sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 18, 2016.
Granted under the Issuer's 2005 Equity Incentive Plan.
25% of each shares vest one year from the date of grant, of March 5, 2010, and 2.0833% vests each month thereafter, provided that Reporting Person continues to be employed by the Issuer.
/s/ Friedhelm Blobel, Ph.D.
2017-04-28